Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | Perioperative genotype-dosed FOLFIRINOX with margin-negative resection in gastroesophageal cancer

Daniel Catenacci • 6 Jul 2020
ESMO WCGIC 2020
Gastroesophageal Cancer Gastrointestinal Cancer Carbotaxel Cisplatin Folfirinox Ipirubucin Irinotecan Oxaliplatin
MAGIC

Daniel Catenacci, MD, University of Chicago, Chicago, IL, outlines pharmacogenomically dosed perioperative FOLFIRINOX in patients with locally advanced gastroesophageal adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Daniel Catenacci

4:10
MAHOGANY: margetuximab and retifanlimab in HER2+, 1L unresectable/metastatic GEA
Daniel Catenacci • 27 Aug 2021
1:43
Gastroesophageal carcinoma with HER2 gene amplification
Daniel Catenacci • 27 Aug 2021
4:11
Personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC
Daniel Catenacci • 27 Aug 2021
2:59
Clinical implications of HER2 in GI cancers
Daniel Catenacci • 19 May 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:16
Entinostat with nivolumab in pancreatic ductal adenocarcinoma
Marina Baretti • 9 Apr 2024
2:11
COMPASSION-15: cadonilimab in advanced gastric cancers
Yelena Janjigian • 8 Apr 2024
1:28
Evolving biomarker driven therapies to overcome gastric cancer tumor resistance
Yelena Janjigian • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals